| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
ARTICLES |
Thyroid Study Unit, Department of Medicine (K.M., K.M., R.Z., L.J.D.), Kovler Viral Oncology Laboratory (R.L.), University of Chicago, Chicago, Illinois 60637; and the Department of Geriatrics (T.T., T.N.), Shinshu University School of Medicine, Matsumoto, Japan
Address all correspondence and requests for reprints to: Leslie J. DeGroot, M.D., Thyroid Study Unit, MC 3090, The University of Chicago, 5841 South Maryland Avenue, Chicago, Illinois 60637.
Herpes simplex virus thymidine kinase (HSVtk) gene transfer followed by ganciclovir administration is a common strategy for experimental cancer therapy. To evaluate the feasibility of using the human calcitonin promoter to target medullary thyroid carcinoma (MTC), we developed adenovirus vectors containing Escherichia coli ß-galactosidase gene under the control of the CALC-I promoter (AdCTlacZ), or the human cytomegalovirus promoter (AdCMVlacZ). ß-galactosidase activity driven by the CALC-I promoter was higher than by the CMV promoter in rat MTC cells after infection with adenovirus vectors. AdCTlacZ induced an equal or lower expression level of ß-galactosidase in TT (human MTC), T98G, Cos1, HepG2, and HeLa cells compared with AdCMVlacZ. To inhibit the growth of MTC cells, we developed two adenovirus vectors, AdCMVtk carrying HSVtk driven by the cytomegalovirus promoter and AdDCTtk containing a human CALC-I minigene under the control of the CALC-I promoter. HSVtk is fused to a portion of calcitonin coded in exon 4 to direct cell-specific regulation of splicing. All cell lines infected with AdCMVtk were rendered sensitive to ganciclovir, whereas T98G and Cos1 cells infected with AdDCTtk were not affected. Cell killing was also observed in HeLa, HepG2, rat MTC and TT cells infected with AdDCTtk.
This article has been cited by other articles:
 |
|
 |
|
  N. Cengic, C. H. Baker, M. Schutz, B. Goke, J. C. Morris, and C. Spitzweg A Novel Therapeutic Strategy for Medullary Thyroid Cancer Based on Radioiodine Therapy following Tissue-Specific Sodium Iodide Symporter Gene Expression J. Clin. Endocrinol. Metab., August 1, 2005; 90(8): 4457 - 4464. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 A. Stift, M. Sachet, R. Yagubian, C. Bittermann, P. Dubsky, C. Brostjan, R. Pfragner, B. Niederle, R. Jakesz, M. Gnant, et al. Dendritic Cell Vaccination in Medullary Thyroid Carcinoma Clin. Cancer Res., May 1, 2004; 10(9): 2944 - 2953. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 L. Barzon, M. Boscaro, and G. Palu Endocrine Aspects of Cancer Gene Therapy Endocr. Rev., February 1, 2004; 25(1): 1 - 44. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. Messina, D. M. T. Yu, G. W. Both, P. L. Molloy, and B. G. Robinson Calcitonin-Specific Transcription and Splicing Targets Gene-Directed Enzyme Prodrug Therapy to Medullary Thyroid Carcinoma Cells J. Clin. Endocrinol. Metab., March 1, 2003; 88(3): 1310 - 1318. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
T. Bachleitner-Hofmann, A. Stift, J. Friedl, R. Pfragner, K. Radelbauer, P. Dubsky, G. Schuller, T. Benko, B. Niederle, C. Brostjan, et al. Stimulation of Autologous Antitumor T-Cell Responses Against Medullary Thyroid Carcinoma Using Tumor Lysate-Pulsed Dendritic Cells J. Clin. Endocrinol. Metab., March 1, 2002; 87(3): 1098 - 1104. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 K. Haupt, F. Siegel, M. Lu, D. Yang, G. Hilken, K. Mann, M. Roggendorf, and B. Saller Induction of a Cellular and Humoral Immune Response against Preprocalcitonin by Genetic Immunization: A Potential New Treatment for Medullary Thyroid Carcinoma Endocrinology, March 1, 2001; 142(3): 1017 - 1023. [Abstract] [Full Text] [PDF]
|
|
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
| Endocrinology | Endocrine Reviews | J. Clin. End. & Metab. |
| Molecular Endocrinology | Recent Prog. Horm. Res. | All Endocrine Journals |
